Medication creates an opportunity, but habits often determine long-term success
Additional Benefits : Cardiometabolic risk factors and physical functioning improvements were noted among semaglutide users
Another meta-analysis of 21 trials in overweight and obese individuals found small but significant reductions in body weight (approximately 0.75 kg), BMI, and body fat percentage compared to placebo
Based on those results, your provider will confirm whether to proceed with the next cycle as-is, adjust the dose, or add or remove companion peptides
N Engl J Med 384(11):9891002 Horn DB, Kahan S, Batterham RL et al Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
Between appetite changes, reduced thirst cues, and occasional nausea, its easy to slip behind on fluids